|
|
| Line 1: |
Line 1: |
| {| style="cellpadding=0; cellspacing= 0; width: 600px;" | | {| style="cellpadding=0; cellspacing= 0; width: 600px;" |
| |- | | |- |
| | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''[[Loading dose]]''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''[[Maintenance dose]]''' | | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Dosage''' |
| |- | | |- |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Acute Setting''''' | | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Agents with proven efficacy''''' |
| |- | | |- |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control in patients without [[accessory pathway]]''''' | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Dofetilide]] (I A)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Creatinine clearance(ml/min): <br> > 60 - 500 mg <br> 40 to 60 - 250 mg <br> 20 to 40 - 125 mg <br> < 20 - contraindicated''''' |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Esmolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''500 mcg/kg IV over 1 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''60 to 200 mcg/kg/min IV''''' | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Flecainide]] (I A)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral: 200 to 300 mg <br> Intravenous: 1.5 to 3.0 mg/kg over 10 to 20 min''''' |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.15 mg/kg IV''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA''''' | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ibutilide]] (I A)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1 mg over 10 min; repeat 1 mg when necessary''''' |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2.5 to 5 mg IV bolus over 2 min; up to 3 doses''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA''''' | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propafenone]] (I A)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral: 600 mg <br> Intravenous: 1.5 to 2.0 mg/kg over 10 to 20 min''''' |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''5 to 15 mg/h IV''''' | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (IIa A) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral:''''' |
| |-
| | : '''''Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total <br> then 200 to 400 mg per day maintenance or 30 mg/kg as single dose''''' <br> |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.075 to 0.15 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
| | : '''''Outpatient: 600 to 800 mg per day divided dose until 10 g total <br> then 200 to 400 mg per day maintenance.''''' <br> |
| |-
| | '''''Intravenous:''''' |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control in patients with [[accessory pathway]]'''''
| | : '''''5 to 7 mg/kg over 30 to 60 min then 1.2 to 1.8 g per day continuous IV or''''' <br> |
| |-
| | : '''''in divided oral doses until 10 g total then 200 to 400 mg per day maintenance.''''' |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIa Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart Rate Control in patients with [[heart failure]] and without [[accessory pathway]]'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIa Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg IV each 2 h, up to 1.5 mg''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily IV or orally'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Non-Acute Setting and Chronic Maintenance Therapy'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses; slow release available, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses; slow release available, orally'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart Rate Control in patients with heart failure and without accessory pathway'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 mg by mouth daily''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIb Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''800 mg daily for 1 wk, orally <br> 600 mg daily for 1 wk, orally <br> 400 mg daily for 4 to 6 wk, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''200 mg daily, orally'''''
| |
| |- | | |- |
| |} | | |} |